Literature DB >> 9015112

The gnotobiotic piglet as a model for studies of disease pathogenesis and immunity to human rotaviruses.

L J Saif1, L A Ward, L Yuan, B I Rosen, T L To.   

Abstract

Gnotobiotic piglets serve as a useful animal model for studies of human rotavirus infections, including disease pathogenesis and immunity. An advantage of piglets over laboratory animal models is their prolonged susceptibility to human rotavirus-induced disease, permitting cross-protection studies and an analysis of active immunity. Major advances in rotavirus research resulting from gnotobiotic piglet studies include: 1) the adaptation of the first human rotavirus to cell culture after passage and amplification in piglets; 2) delineation of the independent roles of the two rotavirus outer capsid proteins (VP4 and VP7) in induction of neutralizing antibodies and cross-protection; and 3) recognition of a potential role for a nonstructural protein (NSP4) in addition to VP4 and VP7, in rotavirus virulence. Current studies of the pathogenesis of group A human rotavirus infections in gnotobiotic piglets in our laboratory have confirmed that villous atrophy is induced in piglets given virulent but not cell culture attenuated human rotavirus (G1, P1A, Wa strain) and have revealed that factors other than villous atrophy may contribute to the early diarrhea induced. A comprehensive examination of these factors, including a proposed role for NSP4 in viral-induced cytopathology, may reveal new mechanisms for induction of viral diarrhea. Finally, to facilitate and improve rotavirus vaccination strategies, our current emphasis is on the identification of correlates of protective active immunity in the piglet model of human rotavirus-induced diarrhea. Comparison of cell-mediated and antibody immune responses induced by infection with a virulent human rotavirus (to mimic host response to natural infection) with those induced by a live attenuated human rotavirus (to mimic attenuated oral vaccines) in the context of homotypic protection has permitted an analysis of correlates of protective immunity. Results of these studies have indicated that the magnitude of the immune response is greatest in lymphoid tissues adjacent to the local site of viral replication (small intestine). Secondly, there was a direct correlation between the degree of protection induced and the level of the intestinal immune response, with significantly higher local immune responses and complete protection induced only after primary exposure to virulent human rotavirus. These studies thus have established basic parameters related to immune protection in the piglet model of human rotavirus-induced disease, verifying the usefulness of this model to examine new strategies for the design and improvement of human rotavirus vaccines.

Entities:  

Mesh:

Year:  1996        PMID: 9015112     DOI: 10.1007/978-3-7091-6553-9_17

Source DB:  PubMed          Journal:  Arch Virol Suppl        ISSN: 0939-1983


  67 in total

1.  Protein Malnutrition Alters Tryptophan and Angiotensin-Converting Enzyme 2 Homeostasis and Adaptive Immune Responses in Human Rotavirus-Infected Gnotobiotic Pigs with Human Infant Fecal Microbiota Transplant.

Authors:  David D Fischer; Sukumar Kandasamy; Francine C Paim; Stephanie N Langel; Moyasar A Alhamo; Lulu Shao; Juliet Chepngeno; Ayako Miyazaki; Huang-Chi Huang; Anand Kumar; Gireesh Rajashekara; Linda J Saif; Anastasia N Vlasova
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

2.  Serum IgG mediates mucosal immunity against rotavirus infection.

Authors:  Larry E Westerman; Harold M McClure; Baoming Jiang; Jeffrey W Almond; Roger I Glass
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-09       Impact factor: 11.205

3.  Toll-like receptor and innate cytokine responses induced by lactobacilli colonization and human rotavirus infection in gnotobiotic pigs.

Authors:  Ke Wen; Marli S P Azevedo; Ana Gonzalez; Wei Zhang; Linda J Saif; Guohua Li; Ahmed Yousef; Lijuan Yuan
Journal:  Vet Immunol Immunopathol       Date:  2008-10-31       Impact factor: 2.046

4.  Comparisons of nucleotide and deduced amino acid sequences of NSP4 genes of virulent and attenuated pairs of group A and C rotaviruses.

Authors:  K O Chang; Y J Kim; L J Saif
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

5.  Characterization of in vivo anti-rotavirus activities of saponin extracts from Quillaja saponaria Molina.

Authors:  Ka Ian Tam; Michael R Roner
Journal:  Antiviral Res       Date:  2011-04-23       Impact factor: 5.970

Review 6.  Immune responses to rotavirus infection and vaccination and associated correlates of protection.

Authors:  Ulrich Desselberger; Hans-Iko Huppertz
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

7.  Infection Dynamics of Hepatitis E Virus in Wild-Type and Immunoglobulin Heavy Chain Knockout JH -/- Gnotobiotic Piglets.

Authors:  Danielle M Yugo; C Lynn Heffron; Junghyun Ryu; Kyungjun Uh; Sakthivel Subramaniam; Shannon R Matzinger; Christopher Overend; Dianjun Cao; Scott P Kenney; Harini Sooryanarain; Thomas Cecere; Tanya LeRoith; Lijuan Yuan; Nathaniel Jue; Sherrie Clark-Deener; Kiho Lee; Xiang-Jin Meng
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

8.  Lactobacilli and Bifidobacteria enhance mucosal B cell responses and differentially modulate systemic antibody responses to an oral human rotavirus vaccine in a neonatal gnotobiotic pig disease model.

Authors:  Sukumar Kandasamy; Kuldeep S Chattha; Anastasia N Vlasova; Gireesh Rajashekara; Linda J Saif
Journal:  Gut Microbes       Date:  2014

9.  Probiotics and colostrum/milk differentially affect neonatal humoral immune responses to oral rotavirus vaccine.

Authors:  Kuldeep S Chattha; Anastasia N Vlasova; Sukumar Kandasamy; Malak A Esseili; Christine Siegismund; Gireesh Rajashekara; Linda J Saif
Journal:  Vaccine       Date:  2013-02-21       Impact factor: 3.641

10.  Prenatally acquired vitamin A deficiency alters innate immune responses to human rotavirus in a gnotobiotic pig model.

Authors:  Anastasia N Vlasova; Kuldeep S Chattha; Sukumar Kandasamy; Christine S Siegismund; Linda J Saif
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.